Month: August 2023

[204 + Pages Research Study] According to a market research study published by Zion Market Research, the demand analysis of Global Esports Market size & share revenue was valued at around USD 1.47 billion in 2022 and is estimated to grow about USD 6.802 billion by 2030, at a CAGR of approximately 21.11% between 2023 and 2030. The key market players are listed in the report with their sales, revenues and strategies are Activision Blizzard, Electronic Arts (EA), Tencent Holdings, Riot Games, Valve Corporation, Ubisoft, Take-Two Interactive, Team Liquid, Cloud9, Fnatic, Complexity Gaming, Gameloft SE, NVIDIA Corporation, Nintendo of America IncG2 Esports, Natus Vincere (Na’Vi), FaZe Clan, Counter Logic Gaming (CLG), Immortals Gaming Club, Envy Gaming, Gen.G Esports, T1 Entertainment & Sports, Virtus.pro, among others. New...

Revenue Increased Significantly by 76% Compared to Q2/2022 CALGARY, Alberta, Aug. 17, 2023 (GLOBE NEWSWIRE) — Tornado Global Hydrovacs Ltd. (“Tornado” or the “Company”) (TSX-V: TGH; OTCQX: TGHLF) today reported its unaudited financial and operating results for the three months period ended June 30, 2023, with comparisons to the same period last year. The unaudited condensed consolidated financial statements and related management discussion and analysis are available on the Company’s issuer profile in Canada on SEDAR at www.sedar.com, the United States at www.otcmarkets.com and on the Company’s web site www.tornadotrucks.com. All amounts reported in this news release are in thousands ($000’s CAD) except per share amounts. Second Quarter 2023 Overview and Recent DevelopmentsThe Company achieved record quarterly Sales, Gross Profit,...

Frontline plc.’s preliminary second quarter 2023 results will be released on Thursday August 24, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section at www.frontlineplc.cy ahead of the conference call. In order to attend the conference call you may do one of the following: a. WebcastGo to the Investor Relations section at www.frontlineplc.cy and follow the “Webcast” link, or access directly from the link below. Frontline plc Q2 2023 Webcast b. Conference Call Participants will need to register online prior to the conference call via the link below. Dial-in details will be available when registered.               Frontline plc Q2 2023 Conference Call A Q&A session will be held after the teleconference/webcast....

– Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter...

Revenue up 18% Y/Y to $116.7 Million, Excluding Discontinued Operations Company Delivers Record Adjusted EBITDA1 of $29.4 Million, up 78% Y/Y, 12% Sequentially, with Adjusted EBITDA Margin of 25% GAAP Loss from Operations Improved 81% Y/Y, 79% Sequentially to $(4.5) Million, Excluding Discontinued Operations MIAMI, Aug. 17, 2023 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the second quarter ended June 30, 2023. Unless otherwise noted, all results are presented in U.S. dollars. The following financial measures are reported as results from continuing operations due to the sale of the Company’s business in Arizona in March 2023, which are reported as discontinued operations....

Phase 1/2 clinical trial initiated evaluating Immatics’ second next-generation half-life extended TCR Bispecific program, TCER® IMA402 targeting PRAME ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on 11 heavily pre-treated patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off; next update in 4Q 2023 Bristol Myers Squibb exercised first opt-in into 2019 cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment Cash and cash equivalents as well as other financial assets not including the recent equity investment by Bristol Myers Squibb amount to $377.7 million1 (€347.6) as of June 30, 2023; updated projected cash runway is late 2025Tuebingen,...